Neuberger Berman Group LLC purchased a new stake in Bioverativ Inc (NASDAQ:BIVV) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 9,872 shares of the biotechnology company’s stock, valued at approximately $563,000.
A number of other hedge funds also recently bought and sold shares of BIVV. Wells Fargo & Company MN bought a new position in shares of Bioverativ during the 3rd quarter worth approximately $124,500,000. Woodford Investment Management Ltd acquired a new stake in Bioverativ during the 3rd quarter worth approximately $85,455,000. Jackson Square Partners LLC acquired a new stake in Bioverativ during the 3rd quarter worth approximately $99,336,000. Old Mutual Global Investors UK Ltd. acquired a new stake in Bioverativ during the 3rd quarter worth approximately $96,827,000. Finally, ValueAct Holdings L.P. acquired a new stake in Bioverativ during the 3rd quarter worth approximately $72,514,000. Hedge funds and other institutional investors own 95.99% of the company’s stock.
Bioverativ Inc (BIVV) opened at $55.39 on Thursday. Bioverativ Inc has a fifty-two week low of $40.00 and a fifty-two week high of $64.41.
BIVV has been the subject of several research reports. Zacks Investment Research cut Bioverativ from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 1st. Royal Bank of Canada initiated coverage on Bioverativ in a report on Thursday, September 14th. They set a “sector perform” rating and a $59.00 price target for the company. Deutsche Bank set a $53.00 price target on Bioverativ and gave the stock a “hold” rating in a report on Monday, November 20th. Piper Jaffray Companies reissued an “overweight” rating and set a $71.00 price target on shares of Bioverativ in a report on Monday, October 23rd. Finally, Argus raised Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a report on Wednesday, September 20th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $60.33.
WARNING: This piece was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.chaffeybreeze.com/2018/01/04/neuberger-berman-group-llc-purchases-new-position-in-bioverativ-inc-bivv.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.